Pricing Log in Create free account

Promis Neurosciences (PMN) vs Pelthos Therapeutics Inc. (PTHS)

Promis Neurosciences and Pelthos Therapeutics Inc. are both Biotechnology companies. Promis Neurosciences and Pelthos Therapeutics Inc. are of similar size ($35.6M and $32.7M). Promis Neurosciences has the higher net margin (0.00% vs −199.5%) and the higher return on invested capital (0.00% vs −82.3%). Across the 15 metrics below, Pelthos Therapeutics Inc. leads on 8 and Promis Neurosciences on 7.

Valuation

Metric PMN PTHS Biotechnology median
P/E n/m n/m 10.60
P/S 16,913.44 0.78 9.40
P/B 0.75 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.28 n/m 0.66
EV/Sales (5,572.97) 1.88 9.02
Earnings yield (324.53%) (276.23%) (32.88%)
Free cash flow yield (113.16%) (126.55%) (23.13%)

Profitability

Metric PMN PTHS Biotechnology median
Gross margin 0.00% 78.59% 68.51%
Operating margin 0.00% (133.42%) 0.00%
Net margin 0.00% (199.50%) 0.00%
Free cash flow margin 0.00% (98.37%) 0.00%
Return on equity (172.30%) 2,161.07% (51.96%)
Return on assets (127.57%) (125.04%) (46.06%)
Return on invested capital 0.00% (82.34%) 0.00%

Growth

Metric PMN PTHS Biotechnology median
Revenue growth (TTM) 450.00% — 6.76%
EPS growth (last fiscal year) (922.18%) (61.12%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric PMN PTHS Biotechnology median
Debt to equity 0.00 (46.58) 0.00
Current ratio 7.85 1.98 4.97
Net debt to EBITDA 0.15 (0.45) 1.01

Dividend

Metric PMN PTHS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PMN PTHS Biotechnology median
Market cap 32.74m 35.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack